Compare Biogen Inc (BIIB) vs FirstEnergy Corp. (FE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs FirstEnergy Corp. — how do they compare? Biogen Inc trades at $197.24 (market cap $28.34B), while FirstEnergy Corp. trades at $48.58 (market cap $28.01B). The key difference: Biogen Inc and FirstEnergy Corp. are close in size by market cap, and FirstEnergy Corp. pays a 3.84% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | FE | |
|---|---|---|
Market Cap | $28.34B | $28.01B |
Sector | Health | Utilities |
52-Week High | $216.63 | $51.91 |
52-Week Low | $122.68 | $40.30 |
Enterprise Value | $30.62B | $56.02B |
Dividend Yield | — | 3.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
FirstEnergy Corp. (FE) trades at $48.43, up 1.06% on the day, with a bullish technical signal supported by moving averages. The stock shows steady revenue growth, reaching $15.09B in 2025, and maintains a net income margin of 6.86%. Analyst consensus is a Buy with a $52.00 price target, reflecting optimism around grid investments and data center demand. Recent news highlights FE's strategic positioning amid rising energy needs and infrastructure upgrades.
Outlook is positive due to strong fundamentals and growth initiatives, but risks include high debt levels and regulatory pressures. The stock offers potential upside from current levels, supported by earnings beats and institutional confidence, though investors should monitor cash flow trends and execution of capital expenditures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →
